Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Active Tonic mTORC1 Signals Shape Baseline Translation in Naive T Cells.

Myers DR, Norlin E, Vercoulen Y, Roose JP.

Cell Rep. 2019 May 7;27(6):1858-1874.e6. doi: 10.1016/j.celrep.2019.04.037.

2.

High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality Predictions.

Mues M, Karra L, Romero-Moya D, Wandler A, Hangauer MJ, Ksionda O, Thus Y, Lindenbergh M, Shannon K, McManus MT, Roose JP.

Cell Rep. 2019 Apr 9;27(2):631-647.e5. doi: 10.1016/j.celrep.2019.03.045.

3.

Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.

Ksionda O, Mues M, Wandler AM, Donker L, Tenhagen M, Jun J, Ducker GS, Matlawska-Wasowska K, Shannon K, Shokat KM, Roose JP.

PLoS One. 2018 May 25;13(5):e0193849. doi: 10.1371/journal.pone.0193849. eCollection 2018.

4.

A Histidine pH sensor regulates activation of the Ras-specific guanine nucleotide exchange factor RasGRP1.

Vercoulen Y, Kondo Y, Iwig JS, Janssen AB, White KA, Amini M, Barber DL, Kuriyan J, Roose JP.

Elife. 2017 Sep 27;6. pii: e29002. doi: 10.7554/eLife.29002.

5.

Tonic Signals: Why Do Lymphocytes Bother?

Myers DR, Zikherman J, Roose JP.

Trends Immunol. 2017 Nov;38(11):844-857. doi: 10.1016/j.it.2017.06.010. Epub 2017 Jul 25. Review.

6.

Tonic LAT-HDAC7 Signals Sustain Nur77 and Irf4 Expression to Tune Naive CD4 T Cells.

Myers DR, Lau T, Markegard E, Lim HW, Kasler H, Zhu M, Barczak A, Huizar JP, Zikherman J, Erle DJ, Zhang W, Verdin E, Roose JP.

Cell Rep. 2017 May 23;19(8):1558-1571. doi: 10.1016/j.celrep.2017.04.076.

7.

RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma.

Chen X, Wu Q, Depeille P, Chen P, Thornton S, Kalirai H, Coupland SE, Roose JP, Bastian BC.

Cancer Cell. 2017 May 8;31(5):685-696.e6. doi: 10.1016/j.ccell.2017.04.002.

8.

Lost GRP on cytotoxicity?

Roose JP.

Nat Immunol. 2016 Nov 16;17(12):1339-1340. doi: 10.1038/ni.3620. No abstract available.

PMID:
27849207
9.

One-way membrane trafficking of SOS in receptor-triggered Ras activation.

Christensen SM, Tu HL, Jun JE, Alvarez S, Triplet MG, Iwig JS, Yadav KK, Bar-Sagi D, Roose JP, Groves JT.

Nat Struct Mol Biol. 2016 Sep;23(9):838-46. doi: 10.1038/nsmb.3275. Epub 2016 Aug 8.

10.

Distinct oncogenic Ras signals characterized by profound differences in flux through the RasGDP/RasGTP cycle.

Mues M, Roose JP.

Small GTPases. 2017 Jan 2;8(1):20-25. doi: 10.1080/21541248.2016.1187323. Epub 2016 May 9.

11.

Human iPS Cell-Derived Neurons Uncover the Impact of Increased Ras Signaling in Costello Syndrome.

Rooney GE, Goodwin AF, Depeille P, Sharir A, Schofield CM, Yeh E, Roose JP, Klein OD, Rauen KA, Weiss LA, Ullian EM.

J Neurosci. 2016 Jan 6;36(1):142-52. doi: 10.1523/JNEUROSCI.1547-15.2016.

12.

RasGRP1 overexpression in T-ALL increases basal nucleotide exchange on Ras rendering the Ras/PI3K/Akt pathway responsive to protumorigenic cytokines.

Ksionda O, Melton AA, Bache J, Tenhagen M, Bakker J, Harvey R, Winter SS, Rubio I, Roose JP.

Oncogene. 2016 Jul 14;35(28):3658-68. doi: 10.1038/onc.2015.431. Epub 2015 Nov 9.

13.

Unexpected insights for anti-EGFR cancer therapy.

Depeille P, Warren RS, Roose JP.

Oncotarget. 2015 Aug 7;6(22):18746-7. No abstract available.

14.

Flavors of EGFR-Ras signals impacting intestinal homeostasis.

Depeille P, Roose JP.

Cell Cycle. 2015;14(20):3205-6. doi: 10.1080/15384101.2015.1084203. No abstract available.

15.

RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth.

Depeille P, Henricks LM, van de Ven RA, Lemmens E, Wang CY, Matli M, Werb Z, Haigis KM, Donner D, Warren R, Roose JP.

Nat Cell Biol. 2015 Jun;17(6):804-15. doi: 10.1038/ncb3175. Epub 2015 May 25.

16.

RasGRP Ras guanine nucleotide exchange factors in cancer.

Ksionda O, Limnander A, Roose JP.

Front Biol (Beijing). 2013 Oct 1;8(5):508-532.

17.

Protein kinase Cδ promotes transitional B cell-negative selection and limits proximal B cell receptor signaling to enforce tolerance.

Limnander A, Zikherman J, Lau T, Leitges M, Weiss A, Roose JP.

Mol Cell Biol. 2014 Apr;34(8):1474-85. doi: 10.1128/MCB.01699-13. Epub 2014 Feb 10.

18.

Rasgrp1 mutation increases naive T-cell CD44 expression and drives mTOR-dependent accumulation of Helios⁺ T cells and autoantibodies.

Daley SR, Coakley KM, Hu DY, Randall KL, Jenne CN, Limnander A, Myers DR, Polakos NK, Enders A, Roots C, Balakishnan B, Miosge LA, Sjollema G, Bertram EM, Field MA, Shao Y, Andrews TD, Whittle B, Barnes SW, Walker JR, Cyster JG, Goodnow CC, Roose JP.

Elife. 2013 Dec 12;2:e01020. doi: 10.7554/eLife.01020.

19.

PLC-γ and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras.

Diaz-Flores E, Goldschmidt H, Depeille P, Ng V, Akutagawa J, Krisman K, Crone M, Burgess MR, Williams O, Houseman B, Shokat K, Sampath D, Bollag G, Roose JP, Braun BS, Shannon K.

Sci Signal. 2013 Dec 3;6(304):ra105. doi: 10.1126/scisignal.2004125.

20.

Regulation of ras exchange factors and cellular localization of ras activation by lipid messengers in T cells.

Jun JE, Rubio I, Roose JP.

Front Immunol. 2013 Sep 4;4:239. doi: 10.3389/fimmu.2013.00239. Review.

21.

Structural analysis of autoinhibition in the Ras-specific exchange factor RasGRP1.

Iwig JS, Vercoulen Y, Das R, Barros T, Limnander A, Che Y, Pelton JG, Wemmer DE, Roose JP, Kuriyan J.

Elife. 2013 Jul 30;2:e00813. doi: 10.7554/eLife.00813.

22.

Biochemical heterogeneity and developmental varieties in T-cell leukemia.

Chakraborty AK, Roose JP.

Cell Cycle. 2013 May 15;12(10):1480-1. doi: 10.4161/cc.24858. Epub 2013 Apr 29. No abstract available.

23.

Activation of extracellular signal-regulated kinase but not of p38 mitogen-activated protein kinase pathways in lymphocytes requires allosteric activation of SOS.

Jun JE, Yang M, Chen H, Chakraborty AK, Roose JP.

Mol Cell Biol. 2013 Jun;33(12):2470-84. doi: 10.1128/MCB.01593-12. Epub 2013 Apr 15.

24.

Dysregulated RasGRP1 responds to cytokine receptor input in T cell leukemogenesis.

Hartzell C, Ksionda O, Lemmens E, Coakley K, Yang M, Dail M, Harvey RC, Govern C, Bakker J, Lenstra TL, Ammon K, Boeter A, Winter SS, Loh M, Shannon K, Chakraborty AK, Wabl M, Roose JP.

Sci Signal. 2013 Mar 26;6(268):ra21. doi: 10.1126/scisignal.2003848.

25.

A phospholipase C-γ1-independent, RasGRP1-ERK-dependent pathway drives lymphoproliferative disease in linker for activation of T cells-Y136F mutant mice.

Kortum RL, Rouquette-Jazdanian AK, Miyaji M, Merrill RK, Markegard E, Pinski JM, Wesselink A, Nath NN, Alexander CP, Li W, Kedei N, Roose JP, Blumberg PM, Samelson LE, Sommers CL.

J Immunol. 2013 Jan 1;190(1):147-58. doi: 10.4049/jimmunol.1201458. Epub 2012 Dec 3.

26.

The membrane environment can promote or suppress bistability in cell signaling networks.

Abel SM, Roose JP, Groves JT, Weiss A, Chakraborty AK.

J Phys Chem B. 2012 Mar 22;116(11):3630-40. doi: 10.1021/jp2102385. Epub 2012 Mar 13.

27.

Basal LAT-diacylglycerol-RasGRP1 signals in T cells maintain TCRα gene expression.

Markegard E, Trager E, Yang CW, Zhang W, Weiss A, Roose JP.

PLoS One. 2011;6(9):e25540. doi: 10.1371/journal.pone.0025540. Epub 2011 Sep 26.

28.

STIM1, PKC-δ and RasGRP set a threshold for proapoptotic Erk signaling during B cell development.

Limnander A, Depeille P, Freedman TS, Liou J, Leitges M, Kurosaki T, Roose JP, Weiss A.

Nat Immunol. 2011 May;12(5):425-33. doi: 10.1038/ni.2016. Epub 2011 Mar 27.

29.

Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras.

Lauchle JO, Kim D, Le DT, Akagi K, Crone M, Krisman K, Warner K, Bonifas JM, Li Q, Coakley KM, Diaz-Flores E, Gorman M, Przybranowski S, Tran M, Kogan SC, Roose JP, Copeland NG, Jenkins NA, Parada L, Wolff L, Sebolt-Leopold J, Shannon K.

Nature. 2009 Sep 17;461(7262):411-4. doi: 10.1038/nature08279. Epub 2009 Sep 2.

30.

Digital signaling and hysteresis characterize ras activation in lymphoid cells.

Das J, Ho M, Zikherman J, Govern C, Yang M, Weiss A, Chakraborty AK, Roose JP.

Cell. 2009 Jan 23;136(2):337-51. doi: 10.1016/j.cell.2008.11.051.

31.

Origin of the sharp boundary that discriminates positive and negative selection of thymocytes.

Prasad A, Zikherman J, Das J, Roose JP, Weiss A, Chakraborty AK.

Proc Natl Acad Sci U S A. 2009 Jan 13;106(2):528-33. doi: 10.1073/pnas.0805981105. Epub 2008 Dec 19.

32.

Unusual interplay of two types of Ras activators, RasGRP and SOS, establishes sensitive and robust Ras activation in lymphocytes.

Roose JP, Mollenauer M, Ho M, Kurosaki T, Weiss A.

Mol Cell Biol. 2007 Apr;27(7):2732-45. Epub 2007 Feb 5.

33.

Intramolecular regulatory switch in ZAP-70: analogy with receptor tyrosine kinases.

Brdicka T, Kadlecek TA, Roose JP, Pastuszak AW, Weiss A.

Mol Cell Biol. 2005 Jun;25(12):4924-33.

34.

A diacylglycerol-protein kinase C-RasGRP1 pathway directs Ras activation upon antigen receptor stimulation of T cells.

Roose JP, Mollenauer M, Gupta VA, Stone J, Weiss A.

Mol Cell Biol. 2005 Jun;25(11):4426-41.

35.

T cell receptor-independent basal signaling via Erk and Abl kinases suppresses RAG gene expression.

Roose JP, Diehn M, Tomlinson MG, Lin J, Alizadeh AA, Botstein D, Brown PO, Weiss A.

PLoS Biol. 2003 Nov;1(2):E53. Epub 2003 Nov 17.

36.

Synthetic protease inhibitors: promising compounds to arrest pathobiologic processes.

Roose JP, Van Noorden CJ.

J Lab Clin Med. 1995 Apr;125(4):433-41. Review. No abstract available.

PMID:
7706897

Supplemental Content

Loading ...
Support Center